Hosted on MSN
Summit Therapeutics Gets A $40 Price Target As Guggenheim Says It Likes Stock At $24, Like It Did At $3
Summit Therapeutics (SMMT) shares were in the spotlight on Thursday after Guggenheim initiated coverage of the stock with a ‘Buy’ rating and a $40 price target. The price target represents a 70% ...
The race cars roll into downtown Camden, S.C., like an old-fashioned circus. Streets are blocked off for the welcome party, where a rock band serenades the crowd with a Jerry Reed country classic: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results